EN DE
Watch Medikaloka Hermina PT for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medikaloka Hermina PT (HEAL) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Medikaloka Hermina PT stock IDR 602, price IDR 480, upside +25.4%, quality 40 out of 100. Rating: undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ID · ISIN ID1000143100

MH Medikaloka Hermina PT logo Thin data Nov 6, 2026

Medikaloka Hermina PT

HEAL · JK
Speculative

The stock costs 20% less than our calculation considers fair.

Fair value 601.87 IDR · Undervalued (20%)
Low debt
Ranks above peers (9/14)
Quality 40/100
Expensive Growth (revenue 5y +10.1 %/yr in IDR)
Thin margins · 5.4% net margin (TTM)
Negative free cash flow
Narrow moat 41/100 · thin data
Thin data
Watch Medikaloka Hermina PT for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

1,739 IDR 468.00 IDR Fair Value 601.87 IDR Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range 468.00 IDR – 1,739 IDR · fair‑value band 421.31 IDR – 774.81 IDR · the 480.00 IDR price screens below the 601.87 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Medikaloka Hermina PT in your weekly email

Every Wednesday you see whether Medikaloka Hermina PT is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Medikaloka Hermina Tbk, together with its subsidiaries, operates a network of hospitals in Indonesia.

Show moreShow less

The company offers services in the areas of medical acupuncture, pediatrics, surgery, plastic and reconstructive surgery, neurosurgery, emergency medicine, forensic and medicolegal, dentistry, clinical nutrition, integrative medicine, cardiology, obstetrics and gynecology, primary care family medicine, nuclear medicine and molecular theranostics, psychiatry, andrology, dietetics, lactation counseling, and dermatology and venereology.

It also provides services in the areas of ophthalmology, clinical microbiology, pediatric neurology, occupational, radiation oncology, orthopedics and traumatology, pulmonology, anatomical pathology, clinical pathology, anesthesiology, internal medicine, psychology, radiology, physical medicine and rehabilitation, neurology, sports medicine specialist, aviation specialist, radiation specialist, otorhinolaryngology, occupational therapy, and urology.

In addition, the company offers digital subtraction angiography, gastroenterology, IVF clinic, sleep and snoring clinic, pain clinic, growth and development clinic, stem cell, palliative care, perinatology ward, integrated stroke, and medical tourism services.

Further, it is involved in investment, service, trading, management consulting, nurse training, and education services. PT Medikaloka Hermina Tbk was founded in 1985 and is headquartered in Jakarta Timur, Indonesia.

Stock analysis

Medikaloka Hermina PT (HEAL) currently trades at 480.00 IDR, while our model-based Fair Value estimate is 601.87 IDR, implying the stock looks roughly 20% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 656.50 IDR per share, and 7 of the 16 models we run sit above the 480.00 IDR price.

Bear case: the Dividend Discount group reads lowest at 82.68 IDR, and 9 of the 16 models stay below the price. Data coverage for this calculation is low.

Scenario range: 421.31 IDR (bear) to 774.81 IDR (bull), the price of 480.00 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Medikaloka Hermina PT reported revenue of 7.1T IDR in FY2025 versus 5.8T IDR in FY2021, a compound +5.2%/yr. Reported net income was 430B IDR in FY2025, compounding −19.0%/yr from FY2021.

Key figures

Market cap 7.3T IDR (≈ $405M) Small · P/E ratio 18.9 · P/S ratio 1.27 · EPS (TTM) 25.44 IDR · Net margin 5.4% · Return on equity 7.3% · Return on assets (EBIT) 11.6% (5-year average) · Operating margin 11.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).

What moves the price

The share trades about 67% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 25%, HEAL screens cheaper than that median.

Fair Value models

Bear 421.31 IDR Fair Value 601.87 IDR Bull 774.81 IDR
Price 480.00 IDR · Upside +25.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (21.75 IDR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 267.26 IDR 269.41 IDR 288.12 IDR 76
EPV 154.23 IDR 182.34 IDR 204.85 IDR 73
ROIC Compounder 154.23 IDR 182.34 IDR 204.85 IDR 71
All 16 models by family
Earnings-Based
Graham-Dodd 191.59 IDR 1,007 IDR 1,393 IDR 63
Lynch FV 276.51 IDR 395.01 IDR 513.52 IDR 61
PEG = 1.0 276.51 IDR 395.01 IDR 513.52 IDR 57
EPV 154.23 IDR 182.34 IDR 204.85 IDR 73
Dividend Discount
Gordon GGM 52.13 IDR 84.12 IDR 106.26 IDR 69
DDM Multi-Stage 52.13 IDR 81.24 IDR 90.77 IDR 67
Multiples
P/E Multiple 464.89 IDR 619.85 IDR 774.81 IDR 63
P/S Multiple 359.23 IDR 478.97 IDR 598.72 IDR 57
P/B Multiple 1,254 IDR 1,672 IDR 2,090 IDR 55
EV/EBIT 487.82 IDR 693.15 IDR 898.49 IDR 64
EV/EBITDA 853.66 IDR 1,181 IDR 1,508 IDR 66
EV/Revenue 311.47 IDR 499.90 IDR 688.32 IDR 52
Asset-Based
NCAV (Graham) 185.76 IDR 248.92 IDR 371.51 IDR 53
Economic Profit
Residual Income 267.26 IDR 269.41 IDR 288.12 IDR 76
ROIC Compounder 154.23 IDR 182.34 IDR 204.85 IDR 71
Growth Earnings
Growth-Adj P/E 421.31 IDR 601.87 IDR 782.43 IDR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 36
How much profit the company makes from its sales and capital
Quality Growth 41
Are margins and returns getting better?
Cashflow 40
Do the profits arrive as real cash?
Financial strength 51
Debt, balance sheet and risk of trouble
Investment 10
Does it invest with discipline instead of growing at any price?
Low Volatility 70
How calm the share price moves, does not count
Price momentum 1
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 71
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+5.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Start year 2020 (pandemic). Over 10 years: +15.4% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−8.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−8.1% vs 26.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 13%
Pace: the 5-year rate starts in 2020 (pandemic)

Watch HEAL, get fair value alerts →

Compare Medikaloka Hermina PT with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 233 stocks

Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside +25.4% · Above median
Profitability
Return on equity (12 months) 7.3% · Below median
Return on assets 4.6% · Above median
Net margin (12 months) 6.9% · Above median
Operating margin (12 months) 11.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) 7.7% · Above median
Dividend yield (12 months) 0.0% · Bottom 25%
Balance sheet
Debt / equity 0.47× · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 18.9× · Cheaper than median
P/B 1.29× · Cheaper than median
P/S (12 months) 1.27× · Cheaper than median
EV/EBITDA 6.7× · Cheapest 25%
PEG 6.27× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)67 · sector 34
FUTURE (revenue growth)39 · sector 30
PAST (return on equity)29 · sector 32
HEALTH (low debt)77 · sector 90
DIVIDEND (yield)0 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $23.40 $46.55 +99% vs HEAL
Aier Eye Hospital Group 300015 ¥9.01 ¥10.88 +21% vs HEAL
DaVita Inc DVA $191.35 $218.90 +14% vs HEAL
HCA Healthcare, Inc HCA $494.99 $547.34 +11% vs HEAL
Tenet Healthcare Corporation THC $283.33 $279.20 −1% vs HEAL
Encompass Health Corporation EHC $137.54 $94.81 −31% vs HEAL
IHH Healthcare Berhad 5225 7.70 MYR 5.23 MYR −32% vs HEAL
Fresenius SE FRE €52.48 €34.77 −34% vs HEAL
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,446 ₹5,234 −38% vs HEAL
Dr. Sulaiman Al Habib Medical Services Group 4013 215.80 SAR 109.45 SAR −49% vs HEAL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medikaloka Hermina PT: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medikaloka Hermina PT Fair Value". https://www.fairvalue-calculator.com/stock/HEAL

Frequently asked questions

Is Medikaloka Hermina PT (HEAL) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 601.87 IDR versus a price of 480.00 IDR, about +25% upside (undervalued).
What is the fair value of HEAL?
Our model-based fair value for Medikaloka Hermina PT is 601.87 IDR (as of Nov 6, 2026), built from audited fundamentals. The current price: 480.00 IDR.
What is the quality score of HEAL?
Medikaloka Hermina PT has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medikaloka Hermina PT (HEAL)?
Our model-based price target is the fair value of 601.87 IDR (as of Nov 6, 2026) from 16 valuation models. Cautious scenario 421.31 IDR, optimistic scenario 774.81 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Medikaloka Hermina PT stock forecast for 2026?
Our models put fair value at 601.87 IDR, about +25% upside versus a price of 480.00 IDR (undervalued). Cautious scenario 421.31 IDR, optimistic scenario 774.81 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Medikaloka Hermina PT (HEAL)?
Medikaloka Hermina PT reported trailing-twelve-month revenue of about 7.4T IDR (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Medikaloka Hermina PT (HEAL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medikaloka Hermina PT it is 601.87 IDR per share (as of Nov 6, 2026), against a price of 480.00 IDR. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Medikaloka Hermina PT stock overvalued or undervalued in 2026?
As of Nov 6, 2026, HEAL trades below its calculated fair value: price 480.00 IDR, fair value 601.87 IDR, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HEAL?
No. The price is what the market pays today (480.00 IDR); the fair value is what the company's own numbers justify (601.87 IDR). For Medikaloka Hermina PT the two are 121.87 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Medikaloka Hermina PT worth?
The market values Medikaloka Hermina PT at about 7.3T IDR (market capitalisation, as of Nov 6, 2026). Per share that is 480.00 IDR; our models calculate a fair value of 601.87 IDR per share.
What do the bullish and bearish scenarios say about HEAL?
Our models span a range for Medikaloka Hermina PT: cautious scenario 421.31 IDR, base 601.87 IDR, optimistic 774.81 IDR per share (as of Nov 6, 2026, price 480.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HEAL?
Medikaloka Hermina PT trades at a price-to-earnings ratio of 18.9 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 601.87 IDR is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings, FY2025 ex one-offs: 48.4. Other multiples: PEG 6.3, P/B 1.3, P/S 1.3, EV/EBITDA 6.7.
What is the PEG ratio of HEAL?
The PEG ratio of Medikaloka Hermina PT is 6.27 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Medikaloka Hermina PT (HEAL)?
Balance-sheet figures for Medikaloka Hermina PT (as of Nov 6, 2026): return on equity 7.3%, debt of 0.47 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is HEAL from its 52-week high?
Medikaloka Hermina PT trades at 480.00 IDR, about 67% below its 52-week high of 1,462 IDR and 3% above the low of 468.00 IDR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 601.87 IDR is for.
Which stocks are comparable to Medikaloka Hermina PT?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medikaloka Hermina PT stock attractive at the current price?
The data as of Nov 6, 2026: price 480.00 IDR, calculated fair value 601.87 IDR (+25%), Quality Score 40/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HEAL calculated?
We run Medikaloka Hermina PT through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 601.87 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Medikaloka Hermina PT currently trades 20% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medikaloka Hermina PT (HEAL)?
The closing price on Nov 6, 2026 was 480.00 IDR. Our model-based fair value is 601.87 IDR, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medikaloka Hermina PT right now?
A fairly wide model range (421.31 IDR to 774.81 IDR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Medikaloka Hermina PT

How large is the market capitalisation of Medikaloka Hermina PT (HEAL)?
The market capitalisation of Medikaloka Hermina PT is 7.3T IDR (≈ $405M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medikaloka Hermina PT (HEAL)?
The price-to-sales ratio of Medikaloka Hermina PT is 1.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medikaloka Hermina PT (HEAL)?
Earnings per share at Medikaloka Hermina PT are 25.44 IDR (price ÷ EPS = P/E 18.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medikaloka Hermina PT (HEAL)?
The net margin of Medikaloka Hermina PT is 5.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medikaloka Hermina PT (HEAL)?
The return on equity (ROE) of Medikaloka Hermina PT is 7.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medikaloka Hermina PT (HEAL)?
On an EBIT basis the return on assets of Medikaloka Hermina PT is 11.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medikaloka Hermina PT (HEAL)?
The operating margin of Medikaloka Hermina PT is 11.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medikaloka Hermina PT (HEAL)?
Revenue at Medikaloka Hermina PT is growing +7.7% versus a year earlier (3y avg +13.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medikaloka Hermina PT (HEAL)?
Earnings per share at Medikaloka Hermina PT are growing −13.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Medikaloka Hermina PT (HEAL) generate?
The free cash flow of Medikaloka Hermina PT is −612B IDR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medikaloka Hermina PT (HEAL) carry?
The net debt of Medikaloka Hermina PT is 2.5T IDR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medikaloka Hermina PT in the live analysis

One click puts Medikaloka Hermina PT on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.